Assembly Biosciences Inc

Assembly Biosciences Inc. a biopharmaceutical company discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334 which is in Phase 1a studies for the treatment of HBV; and ABI-H3733 which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition the company develops Herpesvirus programs such as ABI-5366 HSV-2 a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further Assembly Biosciences Inc. has collaboration agreement with BeiGene Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China Hong Kong Taiwan and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized multi-center and open-label clinical trials as well as agreement with Antios Therapeutics Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research. The company was formerly known as Ventrus Biosciences Inc. and changed its name to Assembly Biosciences Inc. in June 2014. Assembly Biosciences Inc. was incorporated in 2005 and is headquartered in South San Francisco California.